Featured Industry Insights
Can Psilocybin Help Smokers Quit? This Clinical Trial Aims to Find Out
Psilocybin – the primary active ingredient in magic mushrooms – is to be studied in a new clinical trial that will test whether the psychedelic compound can help people quit smoking.
MEG Neuroimaging: The Magnetic Might Keeping Time on the Brain’s Hidden Secrets
Magnetoencephalography (MEG) is a neuroimaging technique that peers inside the brain by detecting incredibly weak magnetic signals produced by neurons. We spoke with Dimitrios Pantazis, who is director of the MEG lab at the Institute’s Martinos Imaging Center, to find out more about this powerful technology.
Latest Industry Insights
The Development of Plant-Based Medicines for Prescription
Despite the fact that herbal or plant-based medicines are widely used and trusted by the public and have been for many years, few have been approved by regulatory agencies in the Western world as prescription medicines. But why have so few botanical medicines been approved?
180 Life Sciences: Developing Drugs To Tackle Distinct Inflammatory Diseases
180 Life Sciences is exploring the use of synthetic cannabidiol (CBD) analogs as a treatment strategy for inflammation and pain, and conducting clinical research focused on repurposing anti-tumor necrosis factor across different fibrotic conditions. Technology Networks recently spoke with Dr James Woody, chief executive officer at 180 Life Sciences, to find out more about the company's research and development pipeline.
Cytisinicline: A Treatment To Help People Battling Nicotine Addiction
The pharmaceutical company Achieve Life Sciences is focused on addressing one of the biggest public health threats globally – tobacco use. Technology Networks had the pleasure of speaking with the company's chief medical officer Cindy Jacobs, MD, PhD, to learn more about cytisinicline, a plant-based alkaloid the company is currently developing as a smoking cessation treatment.
A Bright Future for Sports Neuroscience During the COVID-19 Pandemic
The growing field of sports neuroscience examines the poorly studied relationship between our nervous systems and performance in sporting activities. In this Insight, sports neuroscientist Kamil Celoch discusses the field with Jaime Tartar, professor in the Department of Psychology and Neuroscience at Nova Southeastern University, Florida.
Behind the World-First Export of Jamaican Psilocybin Mushrooms
Mydecine Innovations Group recently announced that it had completed the first harvest and commercial export of legal psychedelic psilocybin mushrooms from Jamaica to Canada. We spoke with Mydecine’s chief scientific officer and co-founder, Rob Roscow, to find out more.
Eliciting the Hormetic Effect: The Importance of Plant Alkaloids for Treatment of Inflammation
Today, plant alkaloids are attracting notice as novel therapies for conditions involving inflammation, such as metabolic syndrome, autoimmune disease and even for aging, which are often characterized by chronic, low-grade over-activation of the immune system. This piece takes a closer look at the need for novel treatments and the best uses for plant alkaloids.
New Clinical Trial Explores Safety of DMT for Substance Use Disorders
Substance use disorders have a debilitating impact on the wellbeing of individuals and their families. Like many other mental health disorders, these conditions have proved stubbornly resistant to treatment. New clinical trials are exploring the safety of the psychedelic DMT for the treatment of these disorders.
How Much Psilocybin Do You Need To Rewire Your Brain?
The therapeutic effects of the psychedelic compound psilocybin, derived from so-called “magic mushrooms” such as Psilocybe semilanceata, are now being more widely understood by medical science. New efforts are trying to tease out what would be a minimal effective dose of psilocybin, one that would have beneficial effects on the brain whilst minimizing hallucinatory experiences. Technology Networks talked to Steven Sadoff of Canadian company Sansero Life Sciences to find out more.
Cell Replacement Therapy – A Promising Treatment for Age-Related Macular Degeneration
Here we share a Q&A with Brian Culley, CEO of Lineage Cell Therapeutics. In this interview, Brian discusses age-related macular degeneration and retinal pigment epithelium transplant therapy.
Exploring the Challenges and Opportunities of Harvesting CTCs
In a recent study, CTCs were harvested to investigate the causes of brain metastasis in non-small cell lung cancer patients. We spoke to Andrew Newland, CEO, ANGLE, to learn more about the study, the challenges of harvesting CTCs and how the Parsortix system overcomes some of these challenges.